drugset / Trial / NCT04552223
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Phase 2
Completed
27 enrolled
Jose Lutzky, MD
Bristol-Myers Squibb · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.
Timeline
- Start
- 2020-11-10
- Primary completion
- 2024-01-04
- Completion
- 2026-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | Intravenous |